COVID-19 vaccination in patients on biologic or targeted-synthetic disease modifying anti-rheumatic drug therapy: A multi center real-world data

Abstract

Objective: To assess the effectiveness of COVID-19 vaccination in patients with rheumatic diseases undergoing biologic (bDMARDs) or targeted-synthetic disease-modifying anti-rheumatic drugs (tsDMARDs).

Methods: This cross-sectional study was conducted at ten rheumatology clinics in Turkey between May 1, 2021, and October 30, 2022. Patients with rheumatic diseases on bDMARD or tsDMARD therapy who received at least two doses of an mRNA or inactivated SARS-CoV-2 vaccine were included. After vaccination, COVID-19 infection rates, adverse events, and rheumatic disease flares were recorded. Data were collected via face-to-face or telephone interviews.

Results: A total of 963 participants were included in the final analysis; 44% were male, and the median age was 49 years. The most frequently observed rheumatic diseases were ankylosing spondylitis and rheumatoid arthritis, accounting for 37.2% and 32.6% of cases, respectively. Adalimumab (19.2%) and infliximab (17.8%) were the most commonly used bDMARDs. Of the participants, 634 (65.9%) received an inactivated vaccine (CoronaVac) and 329 (34.1%) an mRNA vaccine (BioNTech). A total of 502 (52.1%) patients received a booster dose. Following the first, second, and third vaccine doses, adverse event rates were 19.9%, 15.9%, and 26.7%, respectively. Forty-two (4.4%) patients experienced a disease flare within six months after their first vaccination dose. COVID-19 infection occurred in 79 participants (8.2%) after two vaccine doses; most cases were symptomatic but did not require hospitalization. The COVID-19 infection rate was lower in participants who received a booster dose than those who did not (3.4% vs. 8.2%, P<0.001).

Conclusions: Our study indicates that both mRNA and inactivated SARS-CoV-2 vaccines are effective in preventing severe COVID-19 outcomes, with an acceptable rate of adverse events and disease flares among patients with rheumatic diseases on bDMARD or tsDMARD therapy.

Keywords

bDMARDs / Rheumatic diseases / Vaccination / COVID-19 / Adverse events / Flares

Conflict of interest statement

The authors declare no conflict of interest.

Funding

The authors received no extramural funding for the study.

Data availability

The article's underlying data will be shared on reasonable request to the corresponding author.

Authors’ contributions

TDY, FO, AT, AÇ, AMB, GŞ, NY and IS contributed to the conceptualization of the study; TDY, BO, CA, HC, DY, SH, ÖÖI, RPS, HA, BNC, TYİ, YE, SG, AK, NY contributed data curation; TDY, FO, AK, SG contributed to statistical analysis; TDY, FO, SG, ED, ŞE, SSK, SA, SY, YP, GYÇ contributed to preparing and writing the manuscript. All authors reviewed, provided critical review at each stage, and approved the final version of the manuscript. FO is the guarantor.

Publisher’s note

The Publisher of the Journal remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

[1] World Health Organization. Number of COVID-19 deaths reported to WHO. [Online]. Available from: https://data.who.int/dashboards/covid19/deaths. [Accessed on 9 January 2024].

[2] Ahmed S, Gasparyan AY, Zimba O. Comorbidities in rheumatic diseases need special consideration during the COVID-19 pandemic. Rheumatol Int 2021; 41(2): 243-256.

[3] Ge E, Li Y, Wu S, Candido E, Wei X. Association of pre-existing comorbidities with mortality and disease severity among 167 500 individuals with COVID-19 in Canada: A population-based cohort study. PLoS One 2021; 16(10): e0258154.

[4] Marques CDL, Kakehasi AM, Pinheiro MM, Mota LMH, Albuquerque CP, Silva CR, et al. High levels of immunosuppression are related to unfavourable outcomes in hospitalised patients with rheumatic diseases and COVID-19: First results of ReumaCoV Brasil registry. RMD Open 2021; 7(1): e001461.

[5] Conway R, Grimshaw AA, Konig MF, Putman M, Duarte-García A, Tseng LY, et al. SARS-CoV-2 infection and COVID-19 outcomes in rheumatic diseases: A systematic literature review and meta-analysis. Arthritis Rheumatol 2022; 74(5): 766-775.

[6] Strangfeld A, Schäfer M, Gianfrancesco MA, Lawson-Tovey S, Liew JW, Ljung L, et al. Factors associated with COVID-19-related death in people with rheumatic diseases: Results from the COVID-19 global rheumatology alliance physician-reported registry. Ann Rheum Dis 2021; 80(7): 930-942.

[7] Sparks JA, Wallace ZS, Seet AM, Gianfrancesco MA, Izadi Z, Hyrich KL, et al. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 global rheumatology alliance physician registry. Ann Rheum Dis 2021; 80(9): 1137-1146.

[8] Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b 2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med 2021; 384(15): 1412-1423.

[9] Tanriover MD, Doğanay HL, Akova M, Güner HR, Azap A, Akhan S, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): Interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet 2021; 398(10296): 213-222.

[10] Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b 2 mRNA Covid-19 vaccine. N Engl J Med 2020; 383(27): 2603-2615.

[11] Yildirim S, Yilmaz C, Polat G, Baris S, Başyiğit İ, Kaya İ, et al. Clinical characteristics and outcomes of nosocomial COVID-19 in Turkey: A retrospective multicenter study. Asian Pac J Trop Med 2023; 16(8): 347-353.

[12] Sandal A, Cifci AG, Arbak PM. COVID-19 vaccination and associated factors in Turkish healthcare workers practicing chest medicine. Asian Pac J Trop Med 2023; 16(3): 110-118.

[13] Ammitzbøll C, Kragh Thomsen M, Andersen JB, Bartels LE, From Hermansen ML, Dahl JA, et al. COVID-19 vaccination in patients with rheumatic diseases leads to a high seroconversion rate and reduced self-imposed isolation and shielding behaviour. Mod Rheumatol 2023; 33(4): 777-785.

[14] Patel NJ, Wang X, Fu X, Kawano Y, Cook C, Vanni KMM, et al. Factors associated with COVID-19 breakthrough infection among vaccinated patients with rheumatic diseases: A cohort study. Semin Arthritis Rheum 2023; 58: 152108.

[15] Shen C, Risk M, Schiopu E, Hayek SS, Xie T, Holevinski L, et al. Efficacy of COVID-19 vaccines in patients taking immunosuppressants. Ann Rheum Dis 2022; 81(6): 875-880.

[16] Zhou HR, Li GF, Wang XM, Zhou Z, Hu JF, Ye KY, et al. COVID-19 breakthrough infection after four doses of the vaccines:A case report. One Health Bull 2023; 3: 7.

[17] Mehta P, Gasparyan AY, Zimba O, Kitas GD. Systemic lupus erythematosus in the light of the COVID-19 pandemic: Infection, vaccination, and impact on disease management. Clin Rheumatol 2022; 41(9): 2893-2910.

[18] Zavala-Flores E, Salcedo-Matienzo J, Quiroz-Alva A, Berrocal-Kasay A. Side effects and flares risk after SARS-CoV-2 vaccination in patients with systemic lupus erythematosus. Clin Rheumatol 2022; 41(5): 1349-1357.

[19] Braun-Moscovici Y, Kaplan M, Braun M, Markovits D, Giryes S, Toledano K, et al. Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2. Ann Rheum Dis 2021; 80(10): 1317-1321.

[20] Xie Y, Liu Y, Liu Y. The Flare of rheumatic disease after SARS-CoV-2 vaccination: A review. Front Immunol 2022; 13: 919979.

[21] T. C. Sağlık Bakanlığı.[Online]. Available from: https://covid19asi.saglik.gov.tr. [Accessed on 10 January 2024].

[22] Rider LG, Parks CG, Wilkerson J, Schiffenbauer AI, Kwok RK, Noroozi Farhadi P, et al. Baseline factors associated with self-reported disease flares following COVID-19 vaccination among adults with systemic rheumatic disease: Results from the COVID-19 global rheumatology alliance vaccine survey. Rheumatology (Oxford) 2022; 61(SI2): SI143.

[23] Kahn R, Janusz CB, Castro MC, Da A, Matos R, Domingues C, et al. The effectiveness of COVID-19 vaccines in Latin America, 2021: A multicenter regional case-control study. Lancet Reg Heal-Am 2023; 20: 100474.

[24] Machado PM, Lawson-Tovey S, Strangfeld A, Mateus EF, Hyrich KL, Gossec L, et al. Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: Results from the EULAR coronavirus vaccine (COVAX) physician-reported registry. Ann Rheum Dis 2022; 81(5): 695-709.

[25] Pehlivan Ö, Gezer HH. Single-center experience of COVID-19 vaccine in patients with inflammatory rheumatic disease: Real-life data. J Surg Med 2022; 6(9): 792-797.

[26] Cosan F, Demirel OU, Yalcin D, Sonkaya MM, Uluisik IE, Cecen O, et al. Comparison of anti-spike IgG, anti-spike IgA levels and neutralizing antibody activity induced by CoronaVac and BNT162b 2 vaccines in patients with inflammatory rheumatic diseases receiving immunosuppressive therapy. BMC Rheumatol 2023; 7(1): 1-17.

[27] Chen C, Huang S, Geng L, Lai P, Dou H, Zhang H, et al. COVID-19 vaccination and infection status: A cross-sectional survey of patients with rheumatic diseases in China. Rheumatol Int 2024; 44(4): 703-713.

[28] Feikin DR, Higdon MM, Abu-Raddad LJ, Andrews N, Araos R, Goldberg Y, et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: Results of a systematic review and meta-regression. Lancet 2022; 399(10328): 924-944.

[29] CDC. COVID-19 vaccines for people who are moderately or severely immunocompromised.[Online]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/immuno.html. [Accessed on 28 January 2024].

[30] Ahmed S, Gupta L, Kuwana M, Pauling JD, Day J, Ravichandran N, et al. Correlates of breakthrough COVID-19 in vaccinated patients with systemic sclerosis: Survival analysis from a multicentre international patient-reported survey. Rheumatol Int 2024; 44(1): 89-97.

[31] Furer V, Eviatar T, Zisman D, Peleg H, Paran D, Levartovsky D, et al. Immunogenicity and safety of the BNT162b 2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: A multicentre study. Ann Rheum Dis 2021; 80(10): 1330-1338.

[32] Friedman MA, Curtis JR, Winthrop KL. Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases. Ann Rheum Dis 2021; 80: 1255-1265.

[33] Kouhpayeh H, Ansari H. Adverse events following COVID-19 vaccination: A systematic review and meta-analysis. Int Immunopharmacol 2022; 109: 108906.

[34] Esquivel-Valerio JA, Skinner-Taylor CM, Moreno-Arquieta IA, Cardenas-de la Garza JA, Garcia-Arellano G, Gonzalez-Garcia PL, et al. Adverse events of six COVID-19 vaccines in patients with autoimmune rheumatic diseases: A cross-sectional study. Rheumatol Int 2021; 41(12): 2105-2108.

[35] Altan L, Mısırcı S, Yağcı İ, Karacaatlı M, Özkan FÜ, Güner A, et al. How do COVID-19 vaccines affect rheumatic diseases? Arch Rheumatol 2022; 38(1): 75-81.

[36] Aboud FM, Hussein RS, Hassan RM. Safety and reported adverse effects of coronavirus disease-2019 (COVID-19) vaccines in patients with rheumatic diseases. Egypt Rheumatol 2023; 45(2): 133.

[37] Boekel L, Kummer LY, van Dam KPJ, Hooijberg F, van Kempen Z, Vogelzang EH, et al. Adverse events after first COVID-19 vaccination in patients with autoimmune diseases. Lancet Rheumatol 2021; 3(8): e542-e545.

[38] Li X, Tong X, Yeung WWY, Kuan P, Yum SHH, Chui CSL, et al. Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong. Ann Rheum Dis 2022; 81(4): 564-568.

[39] Fong W, Woon TH, Chew LC, Low A, Law A, Poh YJ, et al. Prevalence and factors associated with flares following COVID-19 mRNA vaccination in patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: A national cohort study. Adv Rheumatol 2023; 63(1): 1-9.

[40] Fan Y, Geng Y, Wang Y, Deng X, Li G, Zhao J, et al. Safety and disease flare of autoimmune inflammatory rheumatic diseases: A large real-world survey on inactivated COVID-19 vaccines. Ann Rheum Dis 2021; 81(3): 443.